According to a new study, Covid-19 patients who were administered a novel antibody had fewer symptoms. They were less likely to require hospitalisation or emergency medical care than those who did not receive the therapy. The ongoing Phase II clinical trial tested 3 different doses of LY-CoV555, derived from the blood of a recovered Covid-19 patient. The analysis indicates reduced viral load in outpatients with mild to moderate cases of Covid-19. There was a reduced rate of hospitalisation and e